Associate Professor Linda Lua

Director, PEF

Australian Institute for Bioengineering and Nanotechnology
l.lua@uq.edu.au
+61 7 334 63979

Overview

Associate Professor Linda Lua, founding director of the UQ Protein Expression Facility (PEF); leads a team of research specialists, producing high-quality synthetic proteins to enable and support discovery and translational research. She is internationally recognised for her research-enabling technologies to produce products that range from simple biomolecules to complex biomolecular assemblies such as multi-protein virus-like particles. Applying her expertise, she researches into vaccine technology to address vaccine manufacturing challenges which translated into patented technology platforms. Assoc. Prof. Lua has initiated and led significant industry engagements, both nationally and internationally. Her project management portfolio also includes projects from 16 Universities across Australia as well as public and private research institutes.

Assoc. Prof. Lua’s vision and leadership has established PEF as the leading protein production facility in Australia. Together with her high performing team, she has worked on hundreds of proteins for diverse applications in the areas of structural biology and chemistry, drug screening and discovery, vaccine development and delivery, protein therapeutics, functionalised material, biomedical imaging and agricultural science. She has also developed training programs within the Facility to upskill research students and staff. The Protein Expression Facility has a global reputation for excellence and was awarded the 2016 UQ Award for Excellence in Service and the Chancellor’s Award for Team Excellence in 2013. These awards are recognitions and testaments to Assoc. Prof. Lua’s exemplary leadership.

Research Interests

  • Protein Technologies
  • Bioengineering virus-like particle as vaccines

Research Impacts

Accelerate research

Associate Professor Linda Lua has a broad impact on research through the establishment and progressive expansion of the Protein Expression Facility. Using her extensive experience on recombinant protein production, she has established a robust platform that supports parallel protein production in a comprehensive range of expression hosts (E. coli, yeast, baculovirus/insect cell and mammalian cell). PEF works closely with researchers to tailor expression and purification strategies designed to produce target proteins for their intended use. These partnerships have enabled cutting-edge research for more than 450 researchers in over 60 academic and industry organisations, globally and nationally. Her accomplishment has led to invitations for her to design and facilitate workshops at international higher education and research institutions. She has also provided advice to others on establishing protein facilities.

Vaccine engineering and bioprocessing

In addition to supporting other research groups, Assoc. Prof. Lua applies her technology-focus research on bioengineering virus-like particles as the next generation vaccines to address the speed, cost and efficacy of vaccine manufacturing. Her approach is to evolve technology to engage existing in-country infrastructure towards vaccine production, with the aim of improving the accessibility of vaccines, especially in developing countries. She has engagements and consultations with international vaccine companies and World Health Organisation on various virus-like particle vaccine technology projects.

Qualifications

  • Bachelor of Applied Science (Hons), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Publications

  • Petermann, Julie, Bonnefond, Romain, Mermoud, Isabelle, Rantoen, Dewi, Meynard, Laure, Munro, Christopher, Lua, Linda H. L. and Hue, Thomas (2017) Evaluation of three adjuvants with respect to both adverse effects and the efficacy of antibody production to the Bm86 protein. Experimental and Applied Acarology, 72 3: 303-315. doi:10.1007/s10493-017-0156-4

  • Charlton Hume, Hayley K. and Lua, Linda H. L. (2017) Platform technologies for modern vaccine manufacturing. Vaccine, 35 35: 4480-4485. doi:10.1016/j.vaccine.2017.02.069

  • Fontaine, Frank, Overman, Jeroen, Moustaqil, Mehdi, Mamidyala, Sreeman, Salim, Angela, Narasimhan, Kamesh, Prokoph, Nina, Robertson, Avril A. B., Lua, Linda, Alexandrov, Kirill, Koopman, Peter, Capon, Robert J., Sierecki, Emma, Gambin, Yann, Jauch, Ralf, Cooper, Matthew A., Zuegg, Johannes and Francois, Mathias (2017) Small-molecule inhibitors of the SOX18 transcription factor. Chemistry Chemical Biology, 24 3: 346-359. doi:10.1016/j.chembiol.2017.01.003

View all Publications

Grants

View all Grants

Supervision

View all Supervision

Publications

Book Chapter

  • Lua, Linda H. L. and Chuan, Yap Pang (2012). Advances in protein production technologies. In Ganapathy Subramanian (Ed.), Biopharmaceutical production technology (pp. 43-77) Weinheim, Germany: Wiley-VCH. doi:10.1002/9783527653096.ch2

  • Chuan, Yap Pang, Lua, Linda H. L. and Middelberg, Anton P. J. (2012). Virus-like particle bioprocessing. In Ganapathy Subramanian (Ed.), Biopharmaceutical production technology (pp. 139-163) Weinheim, Germany: Wiley-VCH. doi:10.1002/9783527653096.ch5

Journal Article

Conference Publication

Other Outputs

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Doctor Philosophy — Principal Advisor

  • Doctor Philosophy — Principal Advisor

  • Doctor Philosophy — Principal Advisor

Completed Supervision